Global Short Read Sequencing Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2033

Short Read Sequencing Market Size

• The global short read sequencing market size was valued at USD 8.85 billion in 2025 and is expected to reach USD 293.32 billion by 2033, at a CAGR of 54.90% during the forecast period
• The market growth is largely fueled by the increasing adoption of next-generation sequencing (NGS) technologies, rising demand for high-throughput genomic analysis, and growing applications in clinical diagnostics, personalized medicine, and biomedical research
• Furthermore, advancements in sequencing platforms, reduction in sequencing costs, and the need for rapid and accurate genomic data are accelerating the uptake of short read sequencing solutions, thereby significantly boosting the overall growth of the Short Read Sequencing market

Short Read Sequencing Market Analysis

• Short read sequencing, a high-throughput DNA sequencing technology used for rapid and accurate genomic analysis, is increasingly critical in clinical diagnostics, personalized medicine, genomics research, and drug discovery due to its precision, scalability, and cost-effectiveness
• The growing demand for short read sequencing is primarily driven by the rising need for genomic profiling, biomarker discovery, disease research, and advancements in next-generation sequencing (NGS) platforms that enable faster, high-quality data generation
• North America dominated the short read sequencing market, accounting for approximately 42.7% of the global revenue share in 2025, supported by the presence of leading NGS technology providers, high research funding, advanced healthcare infrastructure, and widespread adoption of genomic technologies in clinical and research applications, particularly in the U.S.
• Asia-Pacific is expected to be the fastest-growing region in the short read sequencing market during the forecast period, with an estimated CAGR of 9.1%, driven by increasing research investments, growing biotechnology and pharmaceutical sectors, expanding healthcare infrastructure, and rising adoption of NGS technologies in emerging economies
• The NGS segment dominated with a revenue share of 78.4% in 2025, owing to its high throughput, scalability, and reduced per-sample cost. NGS is widely used in oncology, reproductive health, metagenomics, and epidemiological research

Report Scope and Short Read Sequencing Market Segmentation    

Short Read Sequencing Market Trends

Advancements in Sequencing Technologies

• A significant and accelerating trend in the global Short Read Sequencing market is the continuous technological advancement in sequencing platforms
  • For instance, in March 2023, Illumina launched the NovaSeq 6000, offering ultra-high throughput sequencing, reducing costs per genome while improving read quality
• These advancements are enabling faster, more accurate, and cost-effective sequencing, supporting large-scale genomic projects, precision medicine, and translational research
• Integration of automated sample preparation systems and cloud-based bioinformatics pipelines is improving workflow efficiency and reducing error rates
• The demand for multi-omics studies, population genomics, and clinical trials is driving adoption across research institutions and pharmaceutical companies
• Decreasing sequencing costs and the availability of versatile reagents are boosting utilization in both academic and commercial research 
• Applications are expanding in plant and animal genomics, metagenomics, and microbiome studies
• Cloud-enabled data analysis and AI-assisted variant calling streamline sequencing workflows
• Emerging markets are witnessing increased adoption due to government genomics initiatives, improved accessibility, and training programs
• Collaborations between sequencing companies and hospitals are promoting clinical research adoption
• Sequencing instruments are becoming more compatible with existing laboratory infrastructure, enabling easier integration
• Overall, these trends are shaping the research landscape and accelerating discoveries in genetics and personalized medicine

Short Read Sequencing Market Dynamics

Driver

Rising Demand for Genomic Research and Personalized Medicine

• The growing focus on precision medicine, pharmacogenomics, and biomarker discovery is a major driver for the Short Read Sequencing market
  • For instance, in June 2024, the Broad Institute launched a large-scale genomic sequencing initiative to support personalized oncology treatments
• Sequencing data is essential for identifying disease-associated mutations, guiding targeted therapies, and understanding genetic variability
• Academic institutions, pharmaceutical companies, and diagnostic labs are expanding sequencing capacity to support translational research and drug development
• Short read sequencing allows cost-effective, high-throughput analysis for population-scale studies and clinical trials
• It provides high accuracy in detecting single nucleotide variants (SNVs) and small insertions/deletions (indels), making it suitable for routine diagnostics
• The rising prevalence of genetic disorders, cancer, and infectious diseases is further fueling demand
• Investments in next-generation sequencing infrastructure are encouraging adoption
• User-friendly bioinformatics tools allow researchers to analyze sequencing data without extensive computational expertise
• Collaborative projects in large consortia, such as Human Genome Project follow-ups, continue to support market expansion
• Regulatory approvals for NGS-based diagnostics strengthen the clinical application of short read sequencing
• Overall, the growing need for precise, actionable genomic data is propelling market growth worldwide

Restraint/Challenge

High Initial Costs and Data Management Complexity

• High initial investment for short read sequencing platforms and infrastructure remains a key restraint
  • For instance, in January 2023, a mid-sized research hospital in Europe delayed implementation of Illumina NovaSeq due to capital expenditure concerns
• Maintenance of instruments, reagent costs, and the need for skilled personnel add to operational expenses
• The massive volume of sequencing data generated requires robust storage, cloud computing, and bioinformatics capabilities
• Data privacy regulations, such as GDPR, complicate data handling and sharing
• Accurate result interpretation demands advanced computational pipelines and trained bioinformatician
• Cost constraints and technical expertise gaps may limit adoption in low-resource regions
• Automation and cloud-based analytics are helping, but complex workflows still pose challenges
• Integration of sequencing data into clinical pipelines can be time-consuming
• Smaller laboratories may face difficulty justifying capital investments for high-throughput platforms
• Addressing barriers through cost reduction, training, and scalable bioinformatics solutions is critical for market growth
• Overall, high costs and technical challenges remain the main adoption barriers

Short Read Sequencing Market Scope

The market is segmented on the basis of product, technology, workflow, application, and end-user.

• By Product

On the basis of product, the Short Read Sequencing market is segmented into Instruments, Consumables, and Services. The Instruments segment dominated the largest market revenue share of 46.5% in 2025, driven by the increasing adoption of high-throughput sequencers across clinical and research laboratories globally. Instruments such as Illumina NovaSeq, NextSeq, and MiSeq offer high accuracy and throughput, supporting large-scale genomics studies. Growing investment in genomics infrastructure by governments and private research institutions strengthens demand. Continuous technological advancements, automation, and cloud-based integration enhance workflow efficiency. Instruments are critical for enabling NGS and Sanger sequencing applications, including oncology, reproductive health, and epidemiology. They also drive recurring demand for consumables and maintenance services. Academic institutions and hospitals prefer owning instruments for in-house sequencing capacity, reducing dependency on external labs. Strategic partnerships between instrument providers and research organizations increase market penetration. The segment also benefits from increased funding in personalized medicine initiatives. Its compatibility with multiple sequencing platforms and sample types makes it a versatile solution across applications.

The Consumables segment is expected to witness the fastest CAGR of 18.9% from 2026 to 2033, fueled by growing demand for reagents, library preparation kits, and sequencing consumables. Consumables are essential for maintaining consistency and high accuracy in both NGS and Sanger workflows. Rising clinical diagnostics, including liquid biopsies and cancer genomics testing, boost adoption. Subscription-based consumable models by vendors encourage repeated purchases. Increasing applications in emerging markets where purchasing instruments is cost-prohibitive also drive growth. Innovation in reagents, including higher sensitivity and lower error rates, supports the segment. Consumables are critical in reproductive health, metagenomics, and epidemiology workflows. Expansion of sequencing services in pharma and biotech enhances demand for consumables. Rising awareness of quality standards and reproducibility further reinforces adoption. Academic and clinical labs continue to purchase consumables to support large-scale studies. Growth is strengthened by collaborations between vendors and research institutions. Emerging trends such as automation and miniaturization of reagents also accelerate market expansion.

• By Technology

On the basis of technology, the market is segmented into Next-Generation Sequencing (NGS) and Sanger Sequencing. The NGS segment dominated with a revenue share of 78.4% in 2025, owing to its high throughput, scalability, and reduced per-sample cost. NGS is widely used in oncology, reproductive health, metagenomics, and epidemiological research. It allows simultaneous processing of multiple samples and supports precision medicine initiatives. Continuous technological advancements, including improved read lengths and faster sequencing times, enhance adoption. NGS integration with automated sample prep and bioinformatics pipelines reduces hands-on time. Large-scale population genomics projects further drive demand. Collaboration between NGS providers and clinical research centers expands adoption in hospitals and academic institutions. Its cost-effectiveness for large studies compared to Sanger sequencing makes it preferred for genomics applications. Integration with cloud-based analytics and AI-powered variant calling improves usability and accuracy. Government initiatives in genomics research also contribute to segment dominance. The NGS segment is crucial for applications in drug development and personalized therapy.

The Sanger Sequencing segment is expected to witness the fastest CAGR of 14.6% from 2026 to 2033, supported by its reliability for small-scale sequencing, validation of NGS results, and clinical applications. It offers high accuracy, reproducibility, and ease of use. Sanger sequencing is preferred for confirmatory studies in pharmacogenomics, oncology, and molecular diagnostics. It remains cost-effective for low-volume applications. Its simplicity ensures adoption in academic labs and smaller clinical setups. Increasing demand for validation studies in precision medicine further drives growth. Vendors are focusing on automated Sanger platforms for higher throughput. The segment is also supported by growing awareness about quality control in genomic workflows. Emerging markets adopting Sanger for targeted testing contribute to growth. Its compatibility with both research and diagnostic applications reinforces its relevance. Expansion of molecular diagnostic labs enhances market potential.

• By Workflow

On the basis of workflow, the market is segmented into Pre-Sequencing, Sequencing, and Data Analysis. The Sequencing segment dominated the largest market revenue share of 52.1% in 2025, as it forms the core step in genomic data generation. High-throughput platforms support large sample volumes and faster run times. Sequencing underpins research in oncology, clinical investigations, and population genomics. Investment in advanced sequencing infrastructure by academic, clinical, and pharmaceutical institutions drives adoption. Integration with automated sample prep reduces manual handling and errors. Sequencing provides reproducible and high-quality data essential for downstream analysis. Vendors offering optimized platforms for diverse applications further boost demand. Cloud integration and real-time data monitoring enhance efficiency. Sequencing also drives demand for consumables, software, and support services. Its critical role in precision medicine strengthens adoption in hospitals and research labs. Strategic collaborations between sequencing providers and clinical centers expand market reach. The segment remains vital for multi-disciplinary genomic studies.

The Data Analysis segment is expected to witness the fastest CAGR of 19.3% from 2026 to 2033, driven by the surge in sequencing data and need for bioinformatics solutions. AI-based analysis, cloud pipelines, and automated variant calling enhance usability. Demand is fueled by clinical interpretation, translational research, and biomarker discovery. Software-as-a-Service models and analytics platforms enable smaller labs to perform complex analysis. Integration with NGS platforms facilitates faster insights. Increasing regulatory requirements for data reproducibility support adoption. Pharma, biotech, and hospitals increasingly rely on advanced analytics for precision medicine. Growth is reinforced by rising demand for multi-omics and integrative studies. Expansion of genomics databases enhances segment relevance. Bioinformatics training programs and collaborative initiatives further promote adoption.

• By Application

On the basis of application, the market is segmented into Oncology, Clinical Investigation, Reproductive Health, HLA Typing/Immune System Monitoring, Metagenomics, Epidemiology and Drug Development, Agrigenomics and Forensics, Consumer Genomics. The Oncology segment accounted for the largest market revenue share of 38.7% in 2025, driven by genetic profiling, tumor mutation detection, and personalized cancer therapies. NGS enables liquid biopsies and tumor genome analysis. Rising cancer prevalence and government funding for early detection boost adoption. Clinical research and development of targeted therapies further enhance demand. Integration with AI and bioinformatics improves mutation detection accuracy. Hospitals and research centers prefer oncology-focused sequencing solutions. Collaborations between oncology labs and sequencing providers strengthen penetration. Adoption of multi-gene panels and targeted therapies supports growth. Increasing precision medicine programs drive segment demand. Oncology remains a focus area for government and private investments. Rising public awareness and preventive genomics contribute to adoption.

The Reproductive Health segment is expected to witness the fastest CAGR of 16.5% from 2026 to 2033, fueled by preimplantation genetic testing, non-invasive prenatal testing, and fertility research. Increasing number of fertility clinics globally supports growth. Awareness about genetic testing in reproductive planning boosts adoption. Rising adoption of NGS and Sanger in reproductive health labs further drives demand. Integration with AI and automated platforms improves testing efficiency. Expanding government and private funding for fertility research supports the segment. Collaborations between diagnostic labs and sequencing providers enhance market reach. Growth is further supported by personalized reproductive healthcare programs.

• By End-User

On the basis of end-user, the market is segmented into Academic Research, Clinical Research, Hospitals and Clinics, Pharma and Biotech Entities, and Other. The Academic Research segment dominated with 44.8% revenue share in 2025, owing to large-scale genomics projects, government-funded initiatives, and wide adoption in universities. Academic institutions invest heavily in instruments, consumables, and analytics platforms. Long-term research projects drive sustained demand. Collaborations with sequencing providers enhance access to advanced platforms.

The Clinical Research segment is expected to witness the fastest CAGR of 17.8% from 2026 to 2033, driven by growing adoption of sequencing in clinical trials, pharmacogenomics studies, and translational medicine. Expansion of clinical labs and pharma collaborations accelerates growth. Additionally, increasing government and private funding for clinical genomics research supports the segment’s expansion. Rising demand for personalized medicine and targeted therapies further fuels adoption of sequencing technologies in clinical settings. Moreover, advancements in high-throughput sequencing platforms and bioinformatics tools enhance efficiency and data accuracy, making clinical research applications more robust and scalable.

Short Read Sequencing Market Regional Analysis

• North America dominated the short read sequencing market, accounting for approximately 43.7% of the global revenue share in 2025
• Supported by the presence of leading next-generation sequencing (NGS) technology providers, high research funding, advanced healthcare infrastructure, and widespread adoption of genomic technologies in clinical and research applications, particularly in the U.S.
• The region benefits from strong investments in genomics research, precision medicine, and molecular diagnostics, driving demand for high-throughput short read sequencing platforms

U.S. Short Read Sequencing Market Insight
The U.S. short read sequencing market captured the largest share within North America in 2025, fueled by growing adoption of NGS in clinical diagnostics, personalized medicine, and biomedical research. Government and private funding for genomic projects, along with well-established biotechnology and pharmaceutical sectors, further contribute to market growth. The increasing integration of NGS into clinical workflows for oncology, genetic disease testing, and infectious disease surveillance is a key driver.

Europe Short Read Sequencing Market Insight
The Europe short read sequencing market is projected to expand at a steady CAGR during the forecast period, driven by increasing government initiatives to support genomic research, rising investments in biotechnology, and growing adoption of NGS in hospitals and research centers. The region’s well-developed healthcare infrastructure and focus on personalized medicine are further supporting the uptake of short read sequencing platforms.

U.K. Short Read Sequencing Market Insight
The U.K. short read sequencing market is expected to grow at a noteworthy CAGR, driven by robust genomic initiatives such as the 100,000 Genomes Project, increasing clinical applications of NGS, and strong research funding across academic and private institutions. Demand for precision medicine and diagnostic testing is further accelerating adoption.

Germany Short Read Sequencing Market Insight
The Germany short read sequencing market is anticipated to expand steadily, fueled by a strong biotechnology and pharmaceutical presence, growing research and development activities, and increasing adoption of NGS technologies in diagnostics and therapeutic research. Government support for innovation and precision medicine programs encourages integration of short read sequencing platforms.

Asia-Pacific Short Read Sequencing Market Insight
The Asia-Pacific short read sequencing market is expected to be the fastest-growing region, registering an estimated CAGR of 9.1% during the forecast period. Growth is driven by increasing research investments, expanding biotechnology and pharmaceutical sectors, rising healthcare infrastructure, and growing adoption of NGS technologies in emerging economies such as China, India, and Japan. The region is witnessing a surge in genomics-based research, clinical testing, and collaborations with global NGS providers.

Japan Short Read Sequencing Market Insight
The Japan short read sequencing market is gaining momentum due to strong research funding, advanced healthcare infrastructure, and a high focus on precision medicine. Growing adoption of NGS for oncology, genetic disorders, and infectious disease testing is fueling market growth, along with collaborations between domestic and international genomics technology providers.

China Short Read Sequencing Market Insight
The China short read sequencing market accounted for the largest revenue share in Asia-Pacific in 2025. Rapid expansion of biotechnology and pharmaceutical sectors, increasing research and development investments, rising demand for clinical diagnostics, and government initiatives supporting genomics research are key factors driving market growth. Growing adoption of NGS technologies across hospitals, research institutes, and private labs is further accelerating the market.

Short Read Sequencing Market Share

The Short Read Sequencing industry is primarily led by well-established companies, including:

• Illumina, Inc. (U.S.)
• Thermo Fisher Scientific (U.S.)
• Pacific Biosciences of California, Inc. (U.S.)
• Agilent Technologies, Inc. (U.S.)
• Roche Sequencing Solutions (Switzerland)
• BGI Genomics (China)
• Oxford Nanopore Technologies (U.K.)
• PerkinElmer, Inc. (U.S.)
• Integrated DNA Technologies (IDT) (U.S.)
• MGI Tech Co., Ltd. (China)
• Novogene Corporation (China)
• Takara Bio Inc. (Japan)
• Eurofins Scientific (Luxembourg)
• GeneDx (U.S.)
• Macrogen, Inc. (South Korea)
• Thermo Fisher Scientific Life Sciences (U.S.)
• Lexogen GmbH (Austria)
• Sengenics, Inc. (Malaysia)

Latest Developments in Global Short Read Sequencing Market

• In March 2023, Illumina launched its first product enabling both long‑ and short‑read sequencing on a single instrument, expanding the flexibility of genomic workflows by allowing labs to generate short‑read data alongside long‑read insights on established NovaSeq systems
• In September 2024, MGI Tech introduced the “SEQ ALL” landscape and Standard MPS 2.0 upgrades for its DNBSEQ platforms, enhancing short‑read performance (higher Q40 base percentages) and broadening throughput options across its T, G, and E series sequencers.
• In February 2025, MGI Tech unveiled the new DNBSEQ‑T1+ mid‑throughput sequencer, capable of completing paired‑end 150 bp short‑read sequencing workflows in as little as 24 hours with high accuracy, representing a major platform expansion for research and clinical users
• In June 2025, MGI Tech’s DNBSEQ‑T1+ received CE marking, enabling broader clinical and research use across regions that recognize CE certification, marking an important regulatory milestone for a key short‑read sequencing platform
• In May 2025, at the ESHG 2025 conference, MGI Tech showcased its advanced sequencing and automation solutions, including the DNBSEQ‑T1+ and new single‑cell library‑preparation automation tools (DNBelab C‑YellowR 16), demonstrating enhanced workflows for short‑read and multi‑omics research

SKU-50464